Cited 3 times in
A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 이정윤 | - |
dc.contributor.author | 이용재 | - |
dc.date.accessioned | 2022-12-22T02:44:54Z | - |
dc.date.available | 2022-12-22T02:44:54Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 0258-851X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191674 | - |
dc.description.abstract | Background/aim: The majority of targeted therapies are focused on BRCA mutations, homologous recombination repair deficiency, and BRCA wild-type platinum-sensitive recurrent ovarian cancer. There is a growing need for platinum-resistant patients without BRCA mutations. Herein, we conducted a phase II multicenter study evaluated the efficacy and safety of bortezomib plus pegylated liposomal doxorubicin (PLD) in patients with BRCA wild-type platinum-resistant recurrent ovarian cancer (NCT03509246). Patients and methods: Ovarian cancer patients with wild-type BRCA who experienced platinum-resistant recurrence after three or less prior treatment cycles from three Institutions were included. All patients received bortezomib, 1.3 mg/m2 subcutaneously (days 1, 4, 8, and 11), and PLD, 40 mg/m2 intravenously (day 4), every 4 weeks. The primary endpoint was best objective response rate (ORR), and secondary endpoints included disease control rate, progression-free survival (PFS), overall survival, and safety. Targeted sequencing was performed to evaluate biomarkers and their potential association with response to treatment. Results: The trial was terminated after 23 patients were recruited because of slow accrual. The median follow-up was 29.5 months. The overall ORR was 8.7% (2/23); partial response was observed in two patients. The median duration of response was 10.5 months, and median PFS was 2.9 months. Treatment-related adverse events (TRAEs) of grade 3/4 were reported in 43.5% of patients. One patient who exhibited TRAEs discontinued treatment. However, grade 4/5 TRAEs were not observed. Mutations in TP53 and CDK12 were detected in 67% (14/21) and 24% (12/21) of patients, respectively. Two patients with partial response harbored mutations in genes related to homologous recombination repair deficiency, including BRCA2, ATM, and CDK12. Conclusion: The combination of bortezomib and PLD was well tolerated; however, antitumor activity was not sufficient to warrant further investigation in ovarian cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Delinassios | - |
dc.relation.isPartOf | IN VIVO | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols* / adverse effects | - |
dc.subject.MESH | Bortezomib / adverse effects | - |
dc.subject.MESH | Carcinoma, Ovarian Epithelial | - |
dc.subject.MESH | Doxorubicin / adverse effects | - |
dc.subject.MESH | Doxorubicin / analogs & derivatives | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoplasm Recurrence, Local / drug therapy | - |
dc.subject.MESH | Neoplasm Recurrence, Local / genetics | - |
dc.subject.MESH | Ovarian Neoplasms* / drug therapy | - |
dc.subject.MESH | Ovarian Neoplasms* / genetics | - |
dc.subject.MESH | Ovarian Neoplasms* / pathology | - |
dc.subject.MESH | Platinum / therapeutic use | - |
dc.subject.MESH | Polyethylene Glycols | - |
dc.title | A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Yong Jae Lee | - |
dc.contributor.googleauthor | Aeran Seol | - |
dc.contributor.googleauthor | Maria Lee | - |
dc.contributor.googleauthor | Jae-Weon Kim | - |
dc.contributor.googleauthor | Hee Seung Kim | - |
dc.contributor.googleauthor | Kidong Kim | - |
dc.contributor.googleauthor | Dong Hoon Suh | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.identifier.doi | 10.21873/invivo.12917 | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A04638 | - |
dc.relation.journalcode | J01043 | - |
dc.identifier.eissn | 1791-7549 | - |
dc.identifier.pmid | 35738633 | - |
dc.subject.keyword | BRCA | - |
dc.subject.keyword | Bortezomib | - |
dc.subject.keyword | antitumor activity | - |
dc.subject.keyword | pegylated liposomal doxorubicin | - |
dc.subject.keyword | platinum-resistant recurrent ovarian cancer | - |
dc.contributor.alternativeName | Kim, Sang Wun | - |
dc.contributor.affiliatedAuthor | 김상운 | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.citation.volume | 36 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1949 | - |
dc.citation.endPage | 1958 | - |
dc.identifier.bibliographicCitation | IN VIVO, Vol.36(4) : 1949-1958, 2022-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.